IE 11 is not supported. For an optimal experience visit our site on another browser.

President of BioCen Natural Products Development Group Announces Health Product Breakthrough in Algae Derived Nutritional Drink Product

SANTA ANA, Calif., Oct. 14, 2010 (GLOBE NEWSWIRE) -- BioCen Natural Products Development Group (Pink Sheets:BNPD)(Formerly Bionic Products, Inc) President Daniel J. Kennedy today commented, "We are pleased to announce that the development of BNPD's first commercial health drink, Vitamin "X" is near completion." For the past 8 weeks, BNPD has been performing test market analysis to determine the best flavor(s) and percentage of Astaxanthin actives for each bottle.
/ Source: GlobeNewswire

SANTA ANA, Calif., Oct. 14, 2010 (GLOBE NEWSWIRE) -- BioCen Natural Products Development Group (Pink Sheets:BNPD)(Formerly Bionic Products, Inc) President Daniel J. Kennedy today commented, "We are pleased to announce that the development of BNPD's first commercial health drink, Vitamin "X" is near completion." For the past 8 weeks, BNPD has been performing test market analysis to determine the best flavor(s) and percentage of Astaxanthin actives for each bottle.

The Company is also developing a 1-fluid ounce concentrated Vitamin "X" shot that will provide a quick alternative to a full beverage product. Each product will contain equal amounts of the beneficial Astaxanthin.

BNPD is continuing to support the efforts of BEHL in cultivation and scale up of Haematococcus for its first commercial site located in Death Valley Junction, California. For the past 3 weeks, the lab staff has traveled to Death Valley Junction to test the Haematococcus that has been strategically placed in test containers on site. The team is very pleased with the growth rate of the Haematococcus and how well this strain is thriving in the harsh DVJ environment.

The BNPD lab department in conjunction with marketing team is working together on furthering their research on the incredible health benefits of Astaxanthin. Such benefits include; reduced risk of cancer, reduction of inflammation, UV protection and muscle recovery, just to name a few.

BNPD is receiving inquires from shareholders wanting know when the inoculation of Haematococcus and harvesting of the Astaxanthin will take place. BNPD's CEO, Ms. Monique Berry stated today that, "We are making great strides and working day and night preparing and planning for inoculation. We have lab staff working at our headquarters in Santa Ana, California, 7 days a week and traveling each week to Death Valley Junction just to monitor the growth of this valuable strain. We will announce the anticipated date of our first inoculation by the end of October."  BNPD's Marketing Director, Marla Kennedy and Product Development Manager, Renate Gass are finalizing the packaging and marketing materials for BNPD products to be sold this year.

The BioCen Natural Products Development Group logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7886

Safe Harbor Statement: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as BNPD or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

CONTACT: BNPD Daniel J. Kennedy, President 714-966-1234 www.bnpdgroup.com BioCentric Energy Monique Berry, President 714-966-1234 www.biocentricenergy.com